NASDAQ$RXRX
Recursion Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Recursion Pharmaceuticals reported first quarter 2022 financial results and provided business updates.
Recursion Pharmaceuticals reported a net loss of $56.0 million for the first quarter of 2022, with total revenue of $5.3 million. The company highlighted progress in its clinical programs, including the enrollment of the first participant in a Phase 2 clinical trial for CCM and advancements in preclinical and discovery programs.
- Enrolled the first participant in Phase 2 clinical trial for CCM and dosed multiple participants.
- Expecting to enroll the first participant in Phase 2/3 clinical trial for progressive NF2-mutated meningiomas in the second quarter 2022.
- Received Fast Track Designation for REC-4881, a potential treatment for FAP, and expect to enroll the first participant in a Phase 2 trial in the third quarter 2022.
- Initiated laboratory efforts and are scaling pilot work to create first partnership-specific maps in an oncology indication with Roche and Genentech.
Headline financials
Revenue & EPS history
Recursion Pharmaceuticals · Revenue · Quarterly
$5.33M
Revenue by segment
Recursion Pharmaceuticals · $5.3M total across 1 segment · Q1 2022
- Collaboration Revenue$5.3M+112.0%100.0%
Forward guidance
Recursion plans to initiate additional clinical trials later in the year and believes its work and partnerships have the potential to positively impact the lives of patients.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-3.1%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.2%
Avg return
30 days after
32%
8 / 25 earnings
Positive
+11.6%
Q1 2023
Best reaction
-16.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -3.3% | -1.8% | |
| Q4 2025 | +6.5% | +2.8% | -16.7% | |
| Q3 2025 | -0.6% | -9.8% | -5.8% | |
| Q1 2025 | -16.5% | -24.0% | -13.9% | |
| Q4 2024 | -12.3% | -16.9% | -29.6% | |
| Q3 2024 | +1.6% | +15.0% | +17.4% | |
| Q2 2024 | -1.3% | +2.7% | -7.1% | |
| Q1 2024 | +0.1% | +17.0% | -0.9% | |
| Q4 2023 | -12.3% | -13.2% | -32.5% | |
| Q3 2023 | -3.0% | +14.7% | +35.0% | |
| Q2 2023 | -0.5% | -13.2% | -24.2% | |
| Q1 2023 | +11.6% | +2.5% | +75.8% | |
| Q4 2022 | +7.1% | +11.4% | -11.3% | |
| Q3 2022 | +8.9% | +32.8% | -0.6% | |
| Q2 2022 | +4.4% | +27.4% | +35.8% | |
| Q1 2022 | -9.4% | +1.4% | +34.4% | |
| Q4 2019 | -0.7% | -1.7% | -14.2% | |
| Q4 2021 | -0.7% | -1.7% | -14.2% | |
| Q3 2020 | -9.1% | -4.3% | -3.2% | |
| Q3 2021 | -9.1% | -4.3% | -3.2% | |
| Q2 2020 | -10.8% | -17.2% | +23.1% | |
| Q2 2021 | -10.8% | -17.2% | +23.1% | |
| Q1 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2021 | -7.1% | -3.6% | +37.8% | |
| Q4 2020 | -7.1% | -3.6% | +37.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro